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ABSTRACT 
Trichomoniasis is the most common sexually transmitted infection caused by the protozoan, 
Trichomonas vaginalis. T. vaginalis infection is often asymptomatic. This infection causes 
vaginal discharge in women and urethritis in men. It has been reported that trichomoniasis is 
associated with serious health complications and it increases the risk of HIV acquisition and 
transmission. The gold standard for trichomoniasis diagnosis is culture, however various point 
of care tests have been approved by the US FDA. Metronidazole is the standard treatment for 
trichomoniasis. Multiple cases of metronidazole-resistance have been reported since 1962. 
Syndromic management of STIs is used to treat multiple infections simultaneously based on 
the signs and symptom with which the patient presents. In South Africa, the vaginal discharge 
syndrome is managed with ceftriaxone, azithromycin and metronidazole.  
Ten T. vaginalis isolate were tested. Each isolate was tested against six combinations of two 
antimicrobials by the checkerboard method, four combinations of three antimicrobials and two 
combinations of four antimicrobials. The results obtained from the checkerboard of two 
antimicrobials were used to design the experiments for three and four antimicrobials 
combinations.  
The MICs for metronidazole ranged between 0.25 – 1 µg/ml and for doxycycline, they ranged 
between 64 – 128 µg/ml. Ceftriaxone and fluconazole showed no antitrichomonal activity. All 
combinations tested has an indifferent effect.  
Combinations of metronidazole and antimicrobials used in syndromic management including 
fluconazole has no effect against T. vaginalis. However, in the combination of metronidazole 
and doxycycline a decrease in the MICs for these antibiotics was observed. Further studies are 
required to test this combination on a larger sample size.   
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CHAPTER ONE 
 
1.1 INTRODUCTION  
Trichomonas vaginalis is an anaerobic parasitic protozoan that causes the sexually transmitted 
infection (STI) trichomoniasis. Trichomoniasis is the most common STI in man, with a 
reported prevalence of 276 million infections annually worldwide [1, 2]. In South African 
women, the prevalence of trichomoniasis ranges from 5% to 49% [3]. T. vaginalis infection is 
often asymptomatic, however when symptoms arise, women experience vaginal discharge, 
pruritus and/or dysuria, vaginitis and cervicitis[2, 4, 5]. In men, it is characterised by urethritis 
(dysuria with or without urethral discharge) which may lead to serious complications such as 
epididymitis, prostatitis and infertility [4, 6-8].  Trichomoniasis has been found to be associated 
with various health complications including pelvic inflammatory disease (PID), significant 
pregnancy complications (premature rupture of membranes, early delivery of the baby, and low 
baby weight), cervical cancer and high risk of acquisition and transmission of HIV [4, 7, 9, 10]. 
Previous studies have shown that infection with T. vaginalis may widen the portal of entry for 
HIV in an HIV-seronegative person whereas in a person infected with both T. vaginalis and 
HIV, it may increase shedding of HIV with increased transmission to others [11].  
It is difficult to diagnose T. vaginalis infection clinically because of the non-specific nature of 
the disease and the problems associated with the diagnostic tests such as sensitivity.  The 
diagnosis of trichomoniasis is in most settings by means of wet-mount microscopy of vaginal 
specimens or urethral secretions. The sensitivity of wet mount is between 35% and 80% when 
compared to culture. Wet mount examination requires a concentration of 104 organisms/ml. 
Lower concentrations of organisms will not be detected [12, 13]. Wet-mount microscopy is the 
most simple and inexpensive diagnostic test, however it is associated with under-diagnosis of 
the disease because of the lack of sensitivity [12]. The disadvantage of wet mount is that since 
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T. vaginalis is unstable in conditions outside the body, the specimen should be examined 
immediately after collection when the microbes are still highly motile.  It becomes difficult to 
discriminate from cells with similar morphology if the typical motility is decreased or lacking 
[13].  
 For the past 40 years, T. vaginalis has been diagnosed using broth culture technique. The 
standard broth is Diamond’s medium and it only requires an inoculum size of 102 
organisms/ml. However, culture techniques are not available or used at the primary healthcare 
level because of the expense and the expertise needed[12]. Over the past decade, PCR has been 
used as a diagnostic test. This technique has a sensitivity of about 90% and a possibility of false 
positives because of DNA from dead organisms after treatment [12]. 
In 1995, syndromic management of STIs was introduced in KwaZulu-Natal [14]. Syndromic 
management is used to treat all possible causes of an STI syndrome simultaneously based on 
the signs and symptoms with which the patient presents. Most health care facilities in 
developing countries lack trained personnel and laboratory equipment required for diagnosis 
of STIs. The WHO has recommended syndromic treatment of STIs in resource poor countries 
since laboratory approach is not practical at the primary healthcare level [15]. In South Africa, 
Vaginal Discharge Syndrome (VDS) is currently managed with metronidazole 2g single dose 
orally, ceftriaxone 250mg single dose intra-muscularly (IM) and azithromycin 1g single dose 
orally [16]. Metronidazole is one of the group of 5-nitroimidazoles [17]. Metronidazole has 
been the standard treatment for trichomoniasis since 1959 [18] and in some countries it is the 
only antibiotic that is approved for trichomoniasis treatment [10]. It is usually prescribed as a 
single dose (2g) or multiple dose regimens of 250 mg, 3 times a day or 500mg, twice a day for 
7 days. Some studies report that metronidazole resistance has been observed in clinical isolates 
derived from treatment failures [18]. Approximately 100 T. vaginalis strains that are 
metronidazole-resistant have been reported in the United States. Some reports have also been 
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published from Russia, Africa and Europe. Patients have been treated with higher doses of 
metronidazole as means of overcoming the problem of metronidazole resistance [17]. The aim 
of this study was to investigate the combined effect of antimicrobial agents used in the 
management of vaginal discharge syndrome on T. vaginalis isolates. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Trichomonas vaginalis  
2.1.1 History 
Trichomonas vaginalis is a parasitic protozoan which colonizes the urogenital tract of humans 
and causes the sexually transmitted infection (STI) trichomoniasis[5, 6, 19]. The organism was 
first described by Alfred F. Donné in 1836 [18].  He observed the motile parasites in the frothy, 
purulent mucous secretions of females that were presenting with vaginitis and vaginal 
discharge [20]. In 1916, Hohne first described T. vaginalis as an etiological or clinical agent of 
the disease [20]. Most research on T. vaginalis focused on microscopic examination and 
biochemical tests to study behavioural and growth characteristics. Studies on immunology and 
pathogenesis of the organism only began in the 1980s upon availability of molecular biology 
and immunological techniques [20].  
 
2.1.2 Morphology  
T. vaginalis is unicellular and its cells vary in size. The average length is 10µm and the width 
is 7µm [6, 8]. This parasite exists in several cellular forms or shapes. The best described forms 
are the pear-shaped (free-swimming) and the amoeboid form [18, 21]. The free-swimming, 
pear-shaped and flagellated cell is usually observed in axenic broth cultures (Figure 1 (A)). The 
amoeboid form is characterised by an increase in surface contact and it is observed upon 
attachment of the protozoan to the vaginal or urethral epithelial cells and extracellular matrix 
(ECM) proteins (Figure 1 B and C) [8, 21]. T. vaginalis has five flagella. The first four are 
located at the anterior end while the fifth flagellum is integrated within the undulating 
membrane [1, 6, 8, 18] . The undulating membrane and the flagella give T. vaginalis the 
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characteristic rapid and jerky movement [6, 8]. T. vaginalis can internalize the flagella under 
adverse growth conditions [6, 8]. The cytoskeleton is made up of actin and tubulin fibers [8].  
The nucleus in T. vaginalis is enclosed in a porous nuclear membrane and is situated in its 
anterior portion. The axostyle (hyaline, rod-like structure) begins at the nucleus and it runs 
through the parasite longitudinally thus protruding through the posterior end of the organism 
[6, 8]. The paraxostylar granules are a distinguishing characteristic of T. vaginalis. These 
granules are arranged in three parallel rows along the axostyle. The protozoan also has 
glycogen granules and phagosomes [6, 8]. The hydrogenosome (a mitochondrion-like 
organelle) is enclosed in a double membrane, has a diameter of 0.5 to 1 µm [8]. It lacks DNA 
and cristae [8].  
 
 
Figure 2.1.2: (A) T. vaginalis parasite as seen in broth culture. (B) T. vaginalis on the 
surface of a vaginal epithelial cell prior to amoeboid transformation. (C) Amoeboid 
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morphology of T. vaginalis as seen when grown on the surface of a cell culture (Arroyo et 
al., 1993 cited by Petrin et al., 1998) [8].  
 
2.1.3 Growth requirements, Nutrition and Metabolism 
T. vaginalis lives in anaerobic environments. However slightly increased levels of oxygen do 
not impair its replication rate as long as the carbon dioxide partial pressure is sufficient [1] .  T. 
vaginalis is unable to produce many macromolecules such as lipids, purines and pyrimidines. 
Hence it is an obligate parasite. The protozoan acquires these nutrients from the vaginal 
secretions or by phagocytosing bacterial and host cells [8, 20]. Thus, the culture media for 
trichomonads needs to have all the vital minerals, vitamins and macromolecules. This is 
provided in the form of serum. Serum provides fatty acids, lipids, trace metals and amino acids. 
Therefore it is essential for the growth of T. vaginalis [8, 20].  
Iron is essential for the maintenance of the activity of ferredoxin and pyruvate-ferredoxin 
oxidoreductase (PFOR) [8]. These enzymes are important for the metabolism of the organism. 
Trichomonas vaginalis ferredoxin (TvFd) is located in the hydrogenosome. Its main function 
is to transfer electrons from PFOR to the hydrogenase. The hydrogenase then transfers these 
electrons to protons to produce hydrogen (H2) [22]. PFOR is located on the membrane of the 
hydrogenosome [23, 24]. This enzyme catalyses the oxidative decarboxylation of pyruvate. 
This reaction is CoA-dependent and it yields CO2 and acetyl-CoA [23-25].  
In T. vaginalis carbohydrate metabolism is fermentative, both under aerobic and anaerobic 
conditions. This carbohydrate metabolism occurs in the hydrogenosome and the cytoplasm. 
The functions of the hydrogenosome include the production of ATP and hydrogen. In addition, 
it provides the site for fermentative oxidation of pyruvate and processing of the carbohydrates 
[8]. The preferred substrate for energy production in T. vaginalis are carbohydrates however 
survival and growth of the trophozoite is sustained by amino acids in environments where 
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carbohydrate levels are insufficient [8]. The carbohydrates provided in culture media are 
glucose or maltose. However, in vaginal secretions glycogen is the main carbohydrate. 
Recently, it was shown that replacing glucose and maltose in the culture media with glycogen 
has the same growth stimulating effect [26] 
Since T. vaginalis lacks the ability to produce purines and pyrimidines, it has to adopt other 
pathways to produce nucleotides [8]. For growth, the trichomonad needs guanine and adenine 
or their nucleosides, uracil and /or uridine, thymidine and cytidine. T. vaginalis lacks most of 
the enzymes that are essential for production of complex phospholipids. Therefore it relies on 
external sources of lipids [8].  
 
2.1.4 Life cycle and Reproduction 
Reproduction in T. vaginalis has been extensively studied. However, it is still not completely 
understood [8]. It has been reported that T. vaginalis only exists as a trophozoite and it lacks 
the cystic stage [6, 8]. The trophozoites reproduce by longitudinal binary fission every 8-12 
hours [27]. The nuclear envelop does not disappear during reproduction in this parasite [6, 8, 
18, 19]. Pseudocyst formation has been observed in trophozoites that are experiencing 
environmental stress [18]. 
 
2.2 Epidemiology 
Trichomoniasis is the most common STI, with a reported prevalence in 2008 of approximately 
276 million new infections annually worldwide [1, 2]. About 90% of trichomoniasis cases 
occur in resource-limited countries [2]. In sub-Saharan Africa, nearly 30 million new cases are 
reported each year [28] and this is likely under-reported. Trichomoniasis has an estimated 
global prevalence of 1% and 8.1% in men and women, respectively [2]. Trichomoniasis has a 
world-wide distribution and it has been observed in all climate conditions [6, 20], racial groups 
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and socio-economic strata [20]. The incidence rate is influenced by various factors such as 
sexual behaviour, age, other STIs, the number of sexual partners [1]. Clinical examination 
methods and laboratory diagnostic techniques also influence the measured incidence [6]. 
Several risk factors associated with acquisition of trichomoniasis and other STIs have been 
identified and these include high risk sexual behaviours, poverty, low educational level, socio-
economic status, multiple sexual partners, HBV and/or HIV infection [29], the presence of 
bacterial vaginosis (BV) [2, 5], drug use, prostitution and older age [2, 4, 5]. Older age is 
thought to be a risk factor in trichomoniasis because the male population is usually not treated 
since the disease is mostly asymptomatic. Although trichomoniasis has the highest prevalence 
compared to other STIs, data describing prevalence and incidence of this infection in the total 
population is insufficient [20, 29].   
 
2.3 Transmission and Pathogenesis 
T. vaginalis can only thrive in humans as their host. The trichomonad is primarily transmitted 
through sexual intercourse [2, 5, 6, 8, 19]. However, it can also be transmitted during artificial 
insemination with infected semen, from mother to infant during delivery and through orogenital 
sexual activities. Orogenital sexual activities cause T. vaginalis infections in the lower 
respiratory tract and pharynx [27].   T. vaginalis invades or colonises the squamous epithelium 
in the genitourinary tract of both males and females [1, 2, 5]. T.vaginalis infection of the 
genitourinary tract causes inflammation of the vagina or urethra [30].  Adhesion of the protozoa 
to the epithelial cells is the first essential step in pathogenesis of T. vaginalis infection [6, 8, 
30, 31]. Adherence to epithelial cells depends on the pH, exposure time and temperature [8]. 
Several adhesion molecules have been identified in T. vaginalis including AP23, AP33, AP51 
and AP65 [8, 20, 30]. Binding of the trichomonad to the epithelial cells is prominently 
facilitated by AP65 and studies have shown that laminin may be the target protein. Gelactin-1, 
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found on cervical epithelial cells, is the only host cell receptor known to bind to T. vaginalis 
lipoglycan (TVLG) [21, 30]. Contributing to the acquisition of nutrients such as iron (Fe) and 
lipids is the capacity of T. vaginalis to lyse and phagocytose host erythrocytes [6, 8, 20, 31]. 
Trichomonal cysteine proteinases (CPs) have been shown to also mediate adherence of the 
trichomonad to epithelial cells as well as haemolysis of red blood cells [6, 8]. 
T. vaginalis has the ability to escape the human immune response. CPs are capable of degrading 
IgG as well as IgA antibodies [1, 6, 8]. It has been documented that T. vaginalis can also 
degrade the C3 portion of complement thus escaping the complement-mediated immune 
response. Escaping the complement pathway is iron dependent, as high levels of iron 
upregulate CP expression [6]. T. vaginalis also uses the host’s plasma proteins to coat itself 
thus avoiding recognition by the immune system as foreign. T. vaginalis can avoid complement 
mediated kill by activating the alternative pathway. It has also been shown that T. vaginalis 
secretes highly immunogenic soluble antigens which have the ability to neutralize cytotoxic T- 
lymphocytes and antibodies [6, 8].  
 
2.4 Clinical manifestations and complications 
T. vaginalis infection is often asymptomatic. The incubation period is usually 4 to 28 days. In 
men, symptomatic infections usually persists for less than 10 days, however in females it may 
persist for months or years [2, 5]. About 50% of women and most men with trichomoniasis 
show no clinical manifestations [8, 28]. When symptoms arise, women experience vaginal 
discharge, pruritus and/or dysuria, vaginitis, cervicitis and colpitis macularis (strawberry 
cervix) [2, 4, 5, 19, 20]. The vaginal discharge in T. vaginalis infection is often yellow-green, 
frothy, foul-smelling and mucopurulent [2, 5, 8]. The vaginal pH of infected females increases 
to above 5 compared to the normal pH of 4.5 [2, 5]. In chronic trichomoniasis, the symptoms 
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are mild and associated with dyspareunia, pruritus and minimal vaginal discharge mixed with 
mucus [6, 8]. In men, trichomoniasis is characterised by urethritis, dysuria, pruritus and urethral 
discharge (clear or mucopurulent). These symptoms are usually self-limiting and of short 
duration [4, 6-8]. 
Trichomoniasis has been found to be associated with serious health complications including 
pelvic inflammatory disease (PID), significant pregnancy complications (premature rupture of 
membranes, early delivery of the baby, and low baby weight), high risk of acquisition and 
transmission of HIV [4, 7, 9, 10, 19, 20, 28, 32], cervical cancer [10, 28], infertility and 
bacterial vaginosis [28]. Previous studies have shown that infection with T. vaginalis may 
widen the portal of entry for HIV in an HIV-seronegative person whereas in a person infected 
with both T. vaginalis and HIV, it may increase shedding of HIV [11, 20]. It has also been 
reported that trichomoniasis is associated with PID in HIV positive females [4, 32]. 
Trichomoniasis in men may lead to serious complications such as epididymitis, prostatitis, 
infertility [7, 8], urethral disease and balanoposthitis  [8].  
 
2.5 Diagnosis 
2.5.1 Microscopic techniques  
The diagnosis of trichomoniasis has for a long time been dependent on microscopic detection 
of the protozoan in vaginal and urethral secretions [12]. Wet mount microscopy is the first 
method that was used for diagnosis of trichomoniasis and it remains the most frequently used 
method [13, 31]. Wet mount examination requires a minimal protozoal concentration of 104 
organisms/ml, organisms fewer than this will not be detected [12, 31]. The sensitivity of wet 
mount microscopy is between 35% and 80% when compared to culture [8, 12, 13, 31]. 
Sensitivity of this method is greatly influenced by the experience of the observer, the presence 
and the concentration of viable and motile trichomonads in the specimen and the period of 
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transportation of the specimen to the laboratory [12, 31]. This technique is the simplest and 
inexpensive diagnostic test[5, 8, 12, 13]. However it is associated with under-diagnosis of the 
disease because of the low sensitivity[5, 12]. The disadvantage of wet mount microscopy is 
that T. vaginalis is unstable in conditions outside the body, therefore, specimens should be 
examined immediately after collection [4, 13].  Outside the human body, T. vaginalis retracts 
its flagella, loses motility and changes shape (becomes rounder). Therefore, it becomes difficult 
to discriminate between trichomonads and cells with similar morphology, in particular white 
blood cells [13].  
Several staining methods such as acridine orange (OA), Giemsa, Fontana-Masson silver stain, 
Periodic Acid-Schiff (PAS), and Leishman stain have been employed for diagnosis of T. 
vaginalis [8, 12, 13, 20, 31]. However, these techniques are associated with loss of morphologic 
and motility characteristics during the fixation and staining steps [8, 12, 31]. Also, it is difficult 
to interpret the stained smears because T. vaginalis can resemble polymorphonuclear 
leukocytes [8, 31].  
Papanicolaou (Pap) smear has a potential as a diagnostic procedure for trichomoniasis [8, 12]. 
However, for this purpose, Pap smears have a sensitivity as low as approximately 60% [4, 19] 
but a specificity of 95% [19]. Moreover, this technique is associated with false positive and 
false negative results [8, 12]. 
 
2.5.2 Culture techniques  
For the past 40 years, T. vaginalis infection has been diagnosed using broth culture technique 
[12] and this has been considered as the gold standard [8, 12, 31, 33]. There are various culture 
media that have been shown to support T. vaginalis growth. These include: Kupferberg 
Trichosel medium, Lash serum medium, Diamond medium, Kupferberg STS medium and 
Difco Kupferberg medium [34].  
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The standard broth is Diamond’s medium [12] and it only requires an inoculum size of  300-
500 organisms/ml [8, 13, 20]. However, culture techniques are not readily available at the 
primary healthcare level mainly because of the need for skilled staff [4, 5, 12]. The advantages 
of broth culture technique include easy interpretation [8, 12, 31], detection of relatively few 
organisms [31] resulting in a higher sensitivity compared to wet mount [5]. The major 
disadvantages of this technique are: it is expensive [4, 5, 12], insensitive in men and time 
consuming [5]. This method generally requires two to seven days of incubation [4, 8, 12] and 
the culture needs to be examined by wet mount microscopy every day [13]. Furthermore, the 
culture technique is prone to bacterial contamination which interferes with detection [12]. 
A practical improvement of the culture technique is the InPouch™ system (BioMed 
Diagnostics, USA). This system allows for easy inoculation, immediate observation, storage 
and transport of the specimen as well as microscopic observation inside the device  [12, 20, 
35]. The InPouch™ medium contains maltose and other sugars, salts, amino acids, peptones 
and antibiotics in a phosphate buffered saline (PBS) base. As shown in figure 2, the InPouch™ 
device is an oxygen resistant plastic pouch which has two chambers. These chambers are joined 
together by a thin passage [35].  
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Figure 2.5.2: Schematic diagram of the InPouch™ system (Barenfanger et al., 2002) [36]. 
 
The top chamber replaces the slide used in wet mount microscopy and is placed under the 
microscope and viewed without being opened [20, 35, 36]. If the microscopic examination is 
negative, the fluid in the top chamber is squeezed into the bottom chamber and further 
incubated [20, 36]. This system has sensitivity between 81-94% and specificity of 100% [35]. 
The cell culture technique can be used to recover or isolate T. vaginalis from specimens. This 
techniques uses different cell lines [8, 20] and it requires the specimen to be treated with 
antimicrobials prior to passage onto the cell culture [12]. Cell culture has high sensitivity and 
it only requires an inoculum of 3 trichomonads/ml [8, 12]. However, this technique is more 
susceptible to bacterial contamination [12], expensive and not suitable for routine and rapid 
diagnosis [8, 12].  
 
2.5.3 Molecular techniques   
Over the past decade, recombinant DNA technology has been used in diagnostic tests for 
trichomoniasis [12]. The Affirm VP III (Becton, Dickinson & Co.; USA) has been approved 
for T. vaginalis diagnosis in women by the US FDA[2, 5, 33]. The Affirm VP III is a nucleic 
acid probe test used for simultaneous detection of significant levels of Gardnerella vaginalis, 
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T. vaginalis [5, 8, 37] and Candida albicans from vaginal specimens. The results are available 
in approximately 45 minutes[2, 5, 33, 37]. It  has been reported that this test might be associated 
with false positives due to the presence of DNA from dead trichomonads after treatment [12]. 
The Affirm VP III test has sensitivity of about 83% and specificity of approximately 97% [2, 
5, 33]. The APTIMA Analyte Specific Reagents test (ASR, manufactured by Gen-Probe, Inc.) 
is also available for the diagnosis of trichomoniasis. This diagnostic test was approved by the 
US FDA in 2011 [2]. Studies have reported sensitivity of about 74 to 98% and specificity of 
about 87 to 98% [2, 5, 33]. Amplicor (Roche Diagnostic Corp.) used for chlamydial and 
gonorrhoea infections has been modified for trichomoniasis diagnosis. This PCR assay can 
detect T. vaginalis in urine, vaginal and endocervical specimen of both men and women [5, 
33].  
Dot-blot hybridization uses a radioactive probe [8, 12, 31]. The disadvantage of this technique 
is that the probe is unstable as a radioactive probe, must be handled with care and requires 
proper disposal. This can be overcome by using a fluorescent-labelled probe [8, 12].  
 
2.5.4 Antibody based techniques  
Trichomonal antibodies can be detected using several techniques including ELISA, 
complement fixation, immune-fluorescence (IFT), hemagglutination and gel diffusion. 
However, these techniques cannot distinguish recent and past infections [8, 12, 31]. Assays 
such as the Fluorescent Direct Immunoassay and Trichomonas Direct Enzyme Immunoassay 
(California Integrated Diagnostics, Benica, Calif.) have been developed for detection of 
trichomonal antigens. These assays employ fluorochrome-labelled and peroxidase-labelled 
monoclonal antibodies to various antigens of T. vaginalis  [8]. These tests are convenient 
because the results are available in 1 hour, thus diagnosis and treatment of the patient are 
possible in a single visit [8]. The OSOM test is based on immunochromatographic capillary 
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flow dipstick technology [2, 5, 20, 33, 38] and the results are available in approximately 10 
minutes[2, 5, 33]. This point of care test has sensitivity of approximately 83% and specificity 
of approximately 97% [2, 5, 20, 33]. The major disadvantage of this test is that it cannot be 
used for men [38]. 
 
2.6 Treatment  
2.6.1 Trichomoniasis treatment 
Before the introduction of 5-nitroimidazoles, treatment of trichomoniasis has been dependent 
on topical vaginal preparations [8]. These were not effective in curing trichomoniasis but they 
relieved symptoms [8]. The 5-nitroimidazole drug family include metronidazole, tinidazole, 
secnidazole, ornidazole, carnidazole, flunidazole and nimorazole [4, 8, 19]. Metronidazole has 
been the standard and approved treatment for trichomoniasis since 1959  [8, 18] and in some 
countries it is the only antibiotic that is approved for treatment of trichomoniasis [10]. The 
CDC treatment guidelines for this infection are metronidazole in a 2g single dose, a multiple 
dose regimen of 500mg, twice a day for 7 days [5, 18, 39] or 250 mg, 3 times a day for 7 days 
[9]. If treatment of the patient is unsuccessful with these regimens, the patient should be treated 
with 2g of metronidazole or tinidazole orally for 5 days [20]. In South Africa, trichomoniasis 
is currently treated with metronidazole 2g single dose, administered orally. If the patient does 
not respond to treatment, then 400mg of metronidazole is orally administered 12 hourly for 7 
days [16]. Metronidazole can also be administered intravenously with a dosage of 500mg to 2g 
[9]. The mechanisms of action of metronidazole include impairment of molecular hydrogen 
production leading to elevated intracellular levels of hydrogen peroxide in the trichomonad 
[18] and  production of toxic nitro-radicals upon activation of the drug [8, 9, 17, 18, 20]. The 
cytotoxic nitro-radicals are thought to bind to DNA, causing strand breakage and thus cell death 
[8, 9, 20]. The approved metronidazole regimens have up to 95% cure rates [5, 9, 20, 39]. 
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Topical metronidazole in intravaginal gels are ineffective for treatment of trichomoniasis [4, 8, 
9, 19].  In 2004, tinidazole was approved by the FDA for treatment of trichomoniasis [33]. It 
is administered as a 2g single dose orally [5, 39]. Tinidazole has cure rates ranging from 86-
100% [20, 39]. Furazolidone and paromomycin have been shown to have anti-trichomonal 
activity [4, 17] and are used in patients with severe adverse effects from the nitro-imidazoles.  
 
2.6.2 Resistance to metronidazole 
Several cases of metronidazole-resistance have been reported in clinical isolates since its 
introduction [18]. Mechanisms of metronidazole-resistance that have been suggested include: 
change in structure of the hydrogenosome, decreased levels of intracellular ferrodoxin, 
decreased activity of the pyruvate-ferredoxin oxidoreductase (PFOR) and ferrodoxin with 
abnormally high redox potential [17]. These mechanisms cause pyruvate fermentation to occur 
in the cytosol instead of in the hydrogenosome, thus preventing the action of the 
nitroimidazoles [17]. 
In aerobic resistance, high levels of oxygen in the cell lead to impaired activation and reduction 
of metronidazole. High levels of oxygen also lead to futile recycling thus limited cell damage 
rather than cell death [17, 18]. It is also thought that in aerobic resistance, ferredoxin gene 
transcription is downregulated resulting in decreased activation of the drug by the cell [8, 20]. 
Anaerobic resistance is characterised by high minimal lethal concentrations (MLCs) during 
susceptibility testing under anaerobic conditions [40, 41]. In this type of resistance, the activity 
of PFOR is reduced or absent, thus no reductive activation of metronidazole [8, 20, 40, 41]. 
The trichomonads are able to replicate in the presence of high levels of metronidazole 
(100µg/mL) in anaerobic resistance [40].  If treatment fails in patients that have been treated 
with high dose regimens (2g for 5 days) of metronidazole and tinidazole, susceptibility testing 
to metronidazole and tinidazole of T. vaginalis should be done [20].  
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2.6.3 Syndromic management 
Many countries including South Africa, Tanzania, Ethiopia and India have implemented 
syndromic management of STIs [42]. In 1995, it was introduced in KwaZulu-Natal [43]. The 
primary objective of syndromic management is to treat STIs based on the signs and symptoms 
that the patient present with instead of being based on a laboratory diagnosis [15, 42-45]. Such 
treatment regimens should cover all causes of the clinical syndrome the patient presents with. 
With this approach, the patient is treated on the day of presentation thus reducing the spread of 
STIs, including HIV [44]. Most health care facilities in developing countries lack trained 
personnel and laboratory equipment required for diagnosis of STIs [43, 44]. The World Health 
Organisation (WHO) has therefore recommended syndromic treatment of STIs in resource poor 
countries since a laboratory approach to diagnosis is not practical at the primary healthcare 
level [44]. Syndromic management is based on the assumption that a group of symptoms and 
clinical signs are associated with a specific syndrome [46] and indicate infection with one or 
more of a group of specific pathogens [42, 46]. Several algorithms have been approved for 
clinical diagnosis of STI syndromes [46]. The major STI syndromes include Male Urethral 
Syndrome (MUS), Vaginal Discharge Syndrome (VDS), Genital Ulcer Disease (GUD), and 
Lower Abdominal Pain (LAP) [45-47].  
The most common STI syndrome in women is VDS [15]. Most of the VDS cases are caused 
by T. vaginalis, bacterial vaginosis (BV), vulvovaginal candidiasis (CA) or any combination 
of these [15]. Less frequent causes are cervicitis with Neisseria gonorrhoeae, Chlamydia 
trachomatis or Mycoplasma genitalium. In South Africa, VDS is currently treated with 
metronidazole 2g single dose orally, ceftriaxone 250mg single dose intra-muscularly (IM) and 
azithromycin 1g single dose orally  (Figure 3) [16]. The advantages of syndromic management 
are that the patients are treated at their first visit to the clinic [3, 42, 45], includes counselling, 
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education and treatment to the patient and their sex partner(s), has a high sensitivity and it 
requires no laboratory diagnosis [42]. The major drawbacks of this approach include low 
specificity because of overtreatment, the VDS algorithm has low sensitivity and specificity and 
asymptomatic infections are undetected since it solely relies on symptoms and signs [42, 44]. 
Effective syndromic management requires regular aetiology and resistance surveillance for the 
different syndromes [45]. 
 
 
Figure 2.6.3: Treatment guideline for Vaginal Discharge Syndrome in South Africa, 2015 
[16]  
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2.7 Antimicrobial susceptibility testing and response to treatment 
For susceptibility testing of bacteria standardised methods have been formulated by 
organisations such as European Committee on Antimicrobial Susceptibility Testing 
(EUCAST), Clinical and Laboratory Standards Institute (CLSI), and the British Society for 
Antimicrobial Chemotherapy (BSAC)[48]. Although no consensus exists regarding the 
methodology with which to test susceptibility of T. vaginalis, the techniques used are based on 
broth dilution. The test is incubated aerobically or anaerobically which results in different 
outcomes. In addition, reading can be done by wet-prep microscopy or directly in tissue culture 
plates using an inverted microscope. Different criteria are used for interpretation leading to 
differences in MIC values obtained by the different methods.   
The checkerboard assay is used to test antibiotic combinations in vitro [49]. This assay is used 
to establish synergism or antagonism of combinations of drugs.   The test is labor extensive 
and time consuming and therefore it is not applied routinely [50]. Synergism of antimicrobial 
agents can also be assessed using the E-test method [51]. However, the E-test cannot be applied 
for T. vaginalis since it needs organisms to grow on agar plates. 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 Culturing and maintenance of isolates 
3.1.1 Trichomonas vaginalis isolates 
Ten randomly chosen clinical isolates of T. vaginalis were obtained from the culture collection 
of the Medical Microbiology laboratory, University of KwaZulu-Natal. The initial plan was to 
use five isolates that are resistant and five susceptible isolates as previously tested in the 
department. However, this could not be achieved since most of the isolates could not be 
revived. 
3.1.2 Culture Medium  
Diamond’s TYM medium was used for culturing and maintaining T. vaginalis isolates. The pH 
was adjusted to pH 6.0 with hydrochloric acid (HCl) before the medium was autoclaved at 
121oC for 15 minutes. The autoclaved medium was cooled to 50oC following which it was 
supplemented with 10 % heat inactivated horse serum (Celtic Molecular Diagnostics, South 
Africa). Vancomycin (5 µg/mL), amphotericin B (5 µg/mL), amikacin (4 µg/mL), 
chloramphenicol (1 µg/mL) and ciprofloxacin (2 µg/mL) was then added. Five milliliter 
volumes of the complete medium were aliquoted in 15 ml polystyrene conical screw-cap tubes 
(NEST) with a diameter of 15 mm and stored at 4oC.  
3.1.3 Revival of T. vaginalis isolates from storage 
Vials of stored axenic cultures were removed from -70oC storage and placed for 2-4 minutes 
in a water bath set at 37oC until completely thawed. The entire contents of each vial were then 
immediately inoculated into Diamond’s media which was pre-warmed to 37oC. The inoculated 
media were placed in a 37oC incubator with 5% CO2. The screw caps of the culture tubes were 
loosely screwed. After 24 hours, the cultures were examined by wet mount microscopy at x400 
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magnification.  If sufficient growth was observed, 500µl was transferred aseptically into 5ml 
of Diamond’s medium. If insufficient numbers of viable trichomonads were present, the culture 
was topped-up to 10 mL with fresh Diamond’s media. This was done to dilute excess DMSO. 
Microscopic examination was thereafter performed after 48 and 72 hours of incubation to 
monitor growth. If growth was observed, a subculture was made into fresh antibiotic-free 
Diamond’s medium.  
 3.1.4 Storage  
Once axenic cultures were confirmed, the isolates were grown in drug free Diamond’s media 
following which 10% dimethyl sulphoxide (DMSO) and 15 % heat inactivated foetal bovine 
serum (FBS) was added. The tubes were then inverted 3-4 times to obtain even distribution of 
the organisms in the broth.  The cultures were then dispensed into cryovials in 2ml aliquots. 
These were then placed at -20oC for approximately 1 hour, then subsequently transferred to -
70oC for long term storage. 
 
3.2 Antimicrobial Susceptibility Testing 
3.2.1 Preparation of antibiotic stock solutions 
Commercially obtained powders of metronidazole, ceftriaxone, doxycycline and fluconazole 
(Sigma Aldrich, USA) were used to prepare stock solutions. The formula below was used to 
calculate the amount of powder required for each antibiotic: 
Required concentration (µg/mL) x volume (ml) x 
100
purity
 = weight (µg) 
Stock solutions were prepared by dissolving the appropriate amount of powder in its respective 
solvent (Table 1). These stock solutions were then aliquoted and stored at -20oC until required. 
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Table 3.2.1: Antibiotics used, their solvents, diluents and stock concentration. 
 
3.2.2 Inoculum preparation and standardization 
Each of the ten T. vaginalis isolates was grown in 5ml drug-free Diamond’s media and 
incubated at 37oC in a 5% CO2 incubator for 24 to 48 hours. For the inoculum preparation, 500 
μl of T. vaginalis culture was added to 5 ml of fresh pre-warmed Diamonds medium and 
incubated as above. After 24 hours, the number of viable trophozoites was counted using a 
Neubauer haemocytometer. The haemocytometer was first disinfected with 70% ethanol and 
then rinsed with sterile distilled water. A glass coverslip was placed over the counting chambers 
of the haemocytometer. A drop of T. vaginalis culture was then placed on the side of the 
coverslip to fill the area under the coverslip by capillary action. Viability of the trophozoites 
was assessed by motility, flipping flagella and/or undulating membrane using a light 
microscope at x400 magnification. The number of viable trophozoites per millilitre was then 
calculated using the following formula: 
Concentration = 
number of trophozoites
squares counted
  x104 
The desired inoculum of 1.5 x 103 trichomonads per well was obtained by dilution with 
antibiotic free pre-warmed Diamond’s medium. 
Antibiotic Solvent Diluent Stock solution 
concentration (µg/mL) 
Metronidazole Acetic Acid Distilled water 6 400 
Doxycycline Distilled water Distilled water 10 240 
Ceftriaxone Distilled water Distilled water 6 400 
Fluconazole DMSO Distilled water 51 200 
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3.2.3 Checkerboard Assay 
Six antibiotic combinations were tested in this experiment (Table 3.2.3a). 
Table 3.2.3a: Antibiotic combinations tested in the checkerboard assay 
No.  Antibiotics in combination 
1.  Metronidazole + Doxycycline 
2. Metronidazole + Ceftriaxone 
3. Metronidazole + Fluconazole  
4. Doxycycline + Ceftriaxone 
5. Doxycycline + Fluconazole 
6. Ceftriaxone + Fluconazole 
 
The Minimal Inhibitory Concentrations (MICs) of metronidazole, doxycycline, ceftriaxone and 
fluconazole (each drug alone and in combination (Table 2)) were determined for each isolate. 
All experiments were performed in triplicate in flat bottomed micro-titer plates. Dilutions of 
all antibiotic stock solutions were prepared to four times the required concentration. Macro- 
dilution was performed for each antibiotic in 15 ml polypropylene tubes using drug free 
Diamond’s medium. Two-fold serial dilutions were performed using pre-diluted antibiotic 
stock solutions for each antibiotic. The highest MIC concentration used in this study for 
metronidazole was chosen per previously published data. For doxycycline we used 
concentrations that were previously tested by Naidoo and Sturm, (2015) [52]. For ceftriaxone, 
we used a concentration range that is normally used for N. gonorrhoeae.   Concentrations for 
fluconazole were chosen based on Naidoo and Sturm, (2015) work [52]. The resulting 
concentrations are shown in Table 3.2.3b. 
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Table 3.2.3b: Concentrations of antimicrobial drugs after broth macro-dilution and final 
concentrations in the checkerboard assay.  
Antibiotic  Macro-broth dilutions (4x) 
(µg/mL) 
Final concentration in the 
assay (µg/mL) 
Metronidazole  16 - 0.25 4 - 0.0625 
Doxycycline  2048 - 32 512 - 8 
Ceftriaxone  64 - 1 16 - 0.25 
Fluconazole  2048 - 32 512 - 8 
 
Figure 3.2.3 shows the set-up of the checkerboard. Fifty (50) µl of antibiotic-free Diamond’s 
media was added in wells A1- A8 and B1- H1 and 100 µl was added in the Growth Control 
(GC) wells (Column 9). Fifty l volumes of each dilution were then transferred to the flat 
bottom 96-well plate (NEST). 50 µl of antibiotic A was added along the x-axis (column 2 to 
column 8) and 50 µl of antibiotic B was added along the y-axis (row B to row H). Each 
microtiter well was then inoculated with 100 µl of T. vaginalis standardized inoculum (1.5x103 
trichomonads per well). The same volume of a suspension with + 1x104 cfu/mL of the bacterial 
or yeast control strains (2.3.5) was added to the remaining columns. The plates were then 
incubated in air-tight 2.5L anaerobic jar containing Anaerogen Gas Packs (Thermo Scientific) 
at 37oC, 5% CO2 incubator. Anaerobic indicator strips (Thermo Scientific) were used to 
monitor anaerobiosis.  The plates were read after 48 and 72 hours of incubation using an 
inverted microscope at x40. The gas pack and indicator strip were changed after the first 
reading (48 hours).   
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Figure 3.2.3: Schematic presentation of the checkerboard assay. The yellow-shaded wells 
only had one antibiotic.  
 
3.2.4 Combinations of three antibiotics 
Four antibiotic combinations were tested in this assay (Table 3.2.4). 
Table 3.2.4: Antibiotic combinations tested in the combination of three antimicrobials 
experiment 
No. Antibiotics in combination 
1. Metronidazole (A) + Doxycycline (B) + Ceftriaxone (C) 
2.  Metronidazole (A)+ Doxycycline (B) + Fluconazole (C) 
3.  Metronidazole (A) + Ceftriaxone (B) + Fluconazole (C) 
4. Doxycycline (A) + Ceftriaxone (B) + Fluconazole (C) 
 
NB- No Bacteria or 
trichomonads 
NA- No Antimicrobial 
GC- Growth Control 
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This assay was designed using results obtained from the checkerboard assay of combinations 
of two antibiotics (Fig 3.2.4). For each isolate, the concentration two times lower than the MIC 
obtained was used for metronidazole and doxycycline. For ceftriaxone and fluconazole, the 
highest concentrations were used (16 and 512 µg/mL, respectively). The working stock 
solutions of antibiotic A and antibiotic B were prepared at concentrations four and eight times 
higher than the required concentration. Antibiotic C working stock solution was prepared to 
four times higher the required concentration. Fifty µl of antibiotic A and B (8x) (each) was 
added in row A and 50 µl of antibiotic A and B (4x) in row B-G. One hundred µl of antibiotic 
C (4x) was added in row A. Two-fold serial dilutions were performed by using 100 µl from 
row A to row G and 100 µl was discarded at row G. The concentration of antibiotic A and B 
remained the same (fixed) in all wells after serial dilutions. Hundred µl of antibiotic-free 
Diamond’s media was added in row H followed by 100 µl of standardized T. vaginalis 
inoculum (1.5x103 trichomonads /well) into each well. Plates were then incubated as previously 
described. Scoring or reading was done after 48 and 72 hours. The assay was performed in 
triplicate for each isolate. 
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Figure 3.2.4: Schematic presentation of the assay for combinations of 3 antimicrobials 
 
3.2.5 Combinations of four antibiotics 
The combination of metronidazole + doxycycline + ceftriaxone + fluconazole was tested in 
two ways:  
1. [Metronidazole + doxycycline + ceftriaxone] (fixed concentration) + fluconazole. 
2. [Metronidazole + doxycycline + fluconazole] (fixed concentration) + ceftriaxone. 
In the first combination, the concentration of metronidazole, doxycycline and ceftriaxone were 
fixed, only fluconazole was serially diluted. In the second combination, the concentration of 
metronidazole, doxycycline and fluconazole were fixed, only ceftriaxone was serially diluted.   
This assay was designed using results obtained from the checkerboard assay of combinations 
of two and three antibiotics. For each isolate, the concentration two times lower than the MIC 
obtained from the checkerboard assay was used for metronidazole and doxycycline. For 
ceftriaxone and fluconazole, the highest concentrations were used (16 and 512 µg/mL, 
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respectively). The working stock solutions of antibiotic A (MTZ) and antibiotic B (DOX) were 
prepared to sixteen and eight times higher the required concentration. Antibiotic C (CTX or 
FLC, depending on the combination) working stock solution was prepared to four times higher 
the required concentration. Working stock solution for antibiotic D (CTX or FLC) was 
prepared to eight times higher the required concentration. Twenty-five µl of antibiotic A (MTZ) 
(16x) and 25 µl of antibiotic B (DOX) (16x) were added in row A. Twenty-five µl of A(8x) 
and 25 µl of B (8x) were added in in row B-G as well as 50µl of antibiotic D (8x) in row A. 
Two-fold serial dilutions were performed from row A to row G using 50 µl and 50 µl was 
discarded at row G. Fifty µl of antibiotic C (4x) was added in all wells. The concentration of 
the first three antibiotics (A, B, C) remained fixed in all wells. One hundred µl of antibiotic-
free Diamond’s media was added in row H. Finally, one hundred µl of standardized T. vaginalis 
inoculum (1.5x103 trichomonads /well) was added into each well. Plates were then incubated 
as previously described. Scoring or reading was done after 48 and 72 hours. The assay was 
performed in triplicate for each isolate. 
 
3.2.6 Controls 
Three bacterial control strains with known MICs were used in this study: Bacteroides fragilis 
ATCC 25285 to test metronidazole concentrations, Klebsiella pneumoniae ATCC 700603 to 
test doxycycline and ceftriaxone concentrations and Candida albicans ATCC 14053 to test 
fluconazole concentrations.  
3.2.7 Scoring of Trichomonas vaginalis  
The plates were read using an inverted microscope (x400), after 48 and 72 hours of incubation. 
T. vaginalis growth and motility was scored according to the scoring criteria in Table 3.2.7. 
The MIC was the lowest antimicrobial concentration with a score of +1.  
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Table 3.2.7: Scoring of Trichomonas vaginalis growth (Upcroft and Upcroft, 2001) 
Score Interpretation 
1+ 0-10 motile parasites; not more than 20% coverage of well surface  
 
2+ > 10 motile parasites; 20% to 50% coverage of the well surface  
 
3+ > 50 % coverage of the well surface = almost confluent growth with much 
motility  
 
4+ confluent growth with full motility  
 
 
3.2.8 Interpretation 
The following formulas were used to calculate the fractional inhibitory concentration (FIC) 
index:                                                                         
The FIC of drug A = MIC of drug A in combination 
                                       MIC of drug A alone 
The FIC of drug B = MIC of drug B in combination  
                                       MIC of drug B alone 
 
The FIC index = FICA + FICB 
Synergy was defined as an FIC index of  ≤ 0.5. Indifference was defined as an FIC of > 0.5 
but of < 4. Antagonism was defined as an FIC index of ≥4 [53]. 
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The study was approved by the Biomedical Research Ethics Committee (BREC) of the 
University of KwaZulu-Natal. Ethics approval number: BE287/15. 
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CHAPTER FOUR 
RESULTS 
4.1 MICs of single antimicrobial drugs 
The distribution of the MICs obtained with metronidazole and doxycycline for the ten isolates 
are shown in table 4.1 a and b. For metronidazole, the values ranged from 0.25 to 1 µg/mL. For 
doxycycline, the MICs were between 64 and 128 µg/mL. Ceftriaxone and fluconazole had no 
antimicrobial activity against T. vaginalis isolates tested (MICs >16µg/mL and >512µg/mL, 
respectively).  A summary of the results is given in table 4.1.c.  
 
Table 4.1a: Distribution of MICs obtained with metronidazole (n=10) 
Antibiotic No of isolates with MIC (μg/mL): 
 
0.0625 0.125 0.25 0.5 1 2 4 
Metronidazole - - 1 4 5 - - 
 
 
Table 4.1b: Distribution of MICs obtained with doxycycline (n=10) 
Antibiotic 
 
No of isolates with MIC (μg/mL): 
 
8 16 32 64 128 256 512 
Doxycycline - - - 5 5 - - 
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Table 4.1c: MIC range, MIC50 and MIC90 of the antimicrobial drugs tested  
Antibiotic MIC range (µg/mL) MIC50 (µg/mL) MIC 90 (µg/mL) 
MTZ 0.25-1 0.5 1 
DOX 64-128 64 128 
CTX >16 >16 >16 
FLC >512 >512 >512 
MTZ- Metronidazole, DOX- Doxycycline, CTX- Ceftriaxone, FLC-Fluconazole 
 
4.2 Combinations of two antimicrobial drugs 
Tables 4.2 a-f show the results for the combinations of two drugs. The MIC of metronidazole 
was decrease in combination with doxycycline for five isolates The MIC of all other isolates 
for all the other antimicrobial agents remained the same, even in combination.  
The FIC Indices for the combination of metronidazole and doxycycline ranged between 0.75 
to 1.125. The interaction between metronidazole and doxycycline was therefore indifferent for 
all isolates.  
The FIC Index for the remaining five drug combinations was 2 for all ten isolates and therefore 
also indifferent.  
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Table 4.2a: Results obtained with metronidazole and doxycycline alone and in 
combination 
 
 
ISOLATE 
MIC alone 
(µg/mL) 
MIC in comb 
(µg/mL) 
FIC  
FIC INDEX 
MTZ DOX MTZ DOX MTZ DOX 
63 0.5 128 0.25 64 0.5 0.5 1 
94 1 64 0.0625 64 0.0625 1 1.0625 
95 1 64 0.0625 64 0.0625 1 1.0625 
264 1 128 0.25 64 0.25 0.5 0.75 
304 0.5 128 0.25 64 0.5 0.5 1 
652 1 128 0.5 32 0.5 0.25 0.75 
696 0.25 64 0.0625 64 0.25 1 1.25 
716 0.5 128 0.25 64 0.5 0.5 1 
727 0.5 64 0.0625 64 0.125 1 1.125 
777 1 64 0.0625 64 0.0625 1 1.0625 
 
Table 4.2b: Results obtained with metronidazole and ceftriaxone alone and in 
combination 
 
 
ISOLATE 
MIC alone 
(µg/mL) 
MIC in comb 
(µg/mL) 
FIC  
FIC 
INDEX MTZ CTX MTZ CTX MTZ CTX 
63 0.5 >16 0.5 >16 1 1 2 
94 1 >16 1 >16 1 1 2 
95 1 >16 1 >16 1 1 2 
264 0.5 >16 0.5 >16 1 1 2 
304 0.5 >16 0.5 >16 1 1 2 
652 1 >16 1 >16 1 1 2 
696 0.25 >16 0.25 >16 1 1 2 
716 0.5 >16 0.5 >16 1 1 2 
727 0.5 >16 0.5 >16 1 1 2 
777 1 >16 1 >16 1 1 2 
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Table 4.2c: Results obtained with metronidazole and fluconazole alone and in 
combination 
 
 
ISOLATE 
MIC alone 
(µg/mL) 
MIC in comb 
(µg/mL) 
FIC  
FIC 
INDEX MTZ FLC MTZ FLC MTZ FLC 
63 0.5 >512 0.5 >512 1 1 2 
94 1 >512 1 >512 1 1 2 
95 1 >512 1 >512 1 1 2 
264 0.5 >512 0.5 >512 1 1 2 
304 0.5 >512 0.5 >512 1 1 2 
652 0.5 >512 0.5 >512 1 1 2 
696 0.25 >512 0.25 >512 1 1 2 
716 0.5 >512 0.5 >512 1 1 2 
727 0.5 >512 0.5 >512 1 1 2 
777 1 >512 1 >512 1 1 2 
 
Table 4.2d: Results obtained with doxycycline and ceftriaxone alone and in combination 
 
 
ISOLATE 
MIC alone 
(µg/mL) 
MIC in comb 
(µg/mL) 
FIC  
FIC 
INDEX DOX CTX DOX CTX DOX CTX 
63 128 >16 128 >16 1 1 2 
94 64 >16 64 >16 1 1 2 
95 64 >16 64 >16 1 1 2 
264 128 >16 128 >16 1 1 2 
304 128 >16 128 >16 1 1 2 
652 128 >16 128 >16 1 1 2 
696 64 >16 64 >16 1 1 2 
716 128 >16 128 >16 1 1 2 
727 64 >16 64 >16 1 1 2 
777 64 >16 64 >16 1 1 2 
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Table 4.2e: Results obtained with doxycycline and fluconazole alone and in combination  
 
Table 4.2f: Results obtained with ceftriaxone and fluconazole alone and in combination 
 
 
 
ISOLATE 
MIC alone 
(µg/mL) 
MIC in comb 
(µg/mL) 
FIC  
FIC 
INDEX DOX FLC DOX FLC DOX FLC 
63 128 >512 128 >512 1 1 2 
94 64 >512 64 >512 1 1 2 
95 64 >512 64 >512 1 1 2 
264 128 >512 128 >512 1 1 2 
304 128 >512 128 >512 1 1 2 
652 128 >512 128 >512 1 1 2 
696 64 >512 64 >512 1 1 2 
716 128 >512 128 >512 1 1 2 
727 64 >512 64 >512 1 1 2 
777 64 >512 64 >512 1 1 2 
 
 
ISOLATE 
MIC alone 
(µg/mL) 
MIC in comb 
(µg/mL) 
FIC  
FIC 
INDEX CTX FLC CTX FLC CTX FLC 
63 >16 >512 >16 >512 1 1 2 
94 >16 >512 >16 >512 1 1 2 
95 >16 >512 >16 >512 1 1 2 
264 >16 >512 >16 >512 1 1 2 
304 >16 >512 >16 >512 1 1 2 
652 >16 >512 >16 >512 1 1 2 
696 >16 >512 >16 >512 1 1 2 
716 >16 >512 >16 >512 1 1 2 
727 >16 >512 >16 >512 1 1 2 
777 >16 >512 >16 >512 1 1 2 
36 
 
4.3 Combinations of three antimicrobial drugs 
In this assay, a fixed concentration of metronidazole and doxycycline was used. The 
concentrations used were obtained from the checkerboard assay (combinations of two 
antimicrobial drugs). A concentration 0.5 x MIC was used for each drug. 
For all four combinations tested, the effect was indifferent for all isolates (FIC Indices = 3) 
(Table 4.3a, b and c). 
Table 4.3a: Results with the MTZ + DOX + CTX and MTZ + DOX + FLC combinations 
 
Isolate 
Concentration 
used (µg/mL) 
3rd antimicrobial 
drug MIC (µg/mL) 
FIC Index 
 MTZ DOX CTX FLC MTZ+DOX+CTX MTZ+DOX+FLC 
63 0.125 32 >16 >512 3 3 
94 0.03125 32 >16 >512 3 3 
95 0.03125 32 >16 >512 3 3 
264 0.125 32 >16 >512 3 3 
304 0.125 32 >16 >512 3 3 
652 0.125 32 >16 >512 3 3 
696 0.03125 32 >16 >512 3 3 
716 0.125 32 >16 >512 3 3 
727 0.03125 32 >16 >512 3 3 
777 0.03125 32 >16 >512 3 3 
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Table 4.3b: Results obtained with the MTZ + CTX + FLC combination 
 
Isolate 
Concentration used 
(µg/mL) 
3rd antimicrobial 
drug MIC (µg/mL) 
FIC Index 
 MTZ CTX FLC MTZ+CTX+FLC 
63 0.25 16 >512 3 
94 0.5 16 >512 3 
95 0.5 16 >512 3 
264 0.25 16 >512 3 
304 0.25 16 >512 3 
652 0.5 16 >512 3 
696 0.125 16 >512 3 
716 0.25 16 >512 3 
727 0.25 16 >512 3 
777 0.5 16 >512 3 
 
Table 4.3c: Results obtained with the DOX + CTX + FLC combination 
 
Isolate 
Concentration used 
(µg/mL) 
3rd antimicrobial 
drug MIC (µg/mL) 
FIC Index 
 DOX CTX FLC DOX+CTX+FLC 
63 64 16 >512 3 
94 32 16 >512 3 
95 32 16 >512 3 
264 64 16 >512 3 
304 64 16 >512 3 
652 64 16 >512 3 
696 32 16 >512 3 
716 64 16 >512 3 
727 32 16 >512 3 
777 32 16 >512 3 
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4.4 Combinations of four antibiotics 
All the combinations in this assay had an indifferent effect on all the isolates tested (FIC Indices 
=4). This is shown in table 4.4a and 4.4b. 
 
Table 4.4a: Results obtained with the MTX + DOX + CTX + FLC combination 
 
Isolate 
Concentration used 
(µg/mL) 
4rd antimicrobial 
drug MIC (µg/mL) 
FIC Index 
 MTZ DOX CTX FLC MTZ+DOX+CTX+FLC 
63 0.125 64 16 >512 4 
94 0.03125 32 16 >512 4 
95 0.03125 32 16 >512 4 
264 0.125 64 16 >512 4 
304 0.125 64 16 >512 4 
652 0.125 64 16 >512 4 
696 0.03125 32 16 >512 4 
716 0.125 64 16 >512 4 
727 0.03125 32 16 >512 4 
777 0.03125 32 16 >512 4 
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Table 4.4b: Results obtained with the MTX + DOX + FLC + CTX combination 
 
Isolate 
Concentration used  
(µg/mL) 
4rd antimicrobial 
drug MIC (µg/mL) 
FIC Index 
 MTZ DOX FLC CTX MTZ+DOX+FLC+CTX 
63 0.125 64 512 >16 4 
94 0.03125 32 512 >16 4 
95 0.03125 32 512 >16 4 
264 0.125 64 512 >16 4 
304 0.125 64 512 >16 4 
652 0.125 64 512 >16 4 
696 0.03125 32 512 >16 4 
716 0.125 64 512 >16 4 
727 0.03125 32 512 >16 4 
777 0.03125 32 512 >16 4 
 
All the combinations tested in this study had an indifferent effect on the isolates.  Table 4.5a, 
b and c show the summary of the results obtained with all the combinations. 
 
 
 
 
 
 
40 
 
Table 4.5a: FIC indices and effect of the combinations of two antimicrobial drugs 
*I – indifferent effect 
 
 
 
Isolate 
MTZ+ DOX MTZ+ CTX MTZ + FLC 
∑ FIC Activity ∑ FIC Activity ∑ FIC Activity 
63 1 I 2 I 2 I 
94 1.0625 I 2 I 2 I 
95 1.0625 I 2 I 2 I 
264 0.75 I 2 I 2 I 
304 1 I 2 I 2 I 
652 0.75 I 2 I 2 I 
696 1.25 I 2 I 2 I 
716 1 I 2 I 2 I 
727 1.125 I 2 I 2 I 
777 1.0625 I 2 I 2 I 
 
Isolate 
DOX + CTX DOX + FLC CTX + FLC 
∑ FIC Activity ∑ FIC Activity ∑ FIC Activity 
63 2 I 2 I 2 I 
94 2 I 2 I 2 I 
95 2 I 2 I 2 I 
264 2 I 2 I 2 I 
304 2 I 2 I 2 I 
652 2 I 2 I 2 I 
696 2 I 2 I 2 I 
716 2 I 2 I 2 I 
727 2 I 2 I 2 I 
777 2 I 2 I 2 I 
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Table 4.5b: FIC indices and effect of the combinations of three antimicrobial drugs 
 
Table 4.5c: FIC indices and effect of the combinations of four antimicrobial drugs 
 
 
 
 
 
 
 
 
 
 
Isolate 
MTZ+DOX+CTX MTZ+DOX+FLC MTZ+CTX+FLUC DOX+CTX+FLC 
∑ FIC Activity ∑ FIC Activity ∑ FIC Activity ∑ FIC Activity 
63 3 I 3 I 3 I 3 I 
94 3 I 3 I 3 I 3 I 
95 3 I 3 I 3 I 3 I 
264 3 I 3 I 3 I 3 I 
304 3 I 3 I 3 I 3 I 
652 3 I 3 I 3 I 3 I 
696 3 I 3 I 3 I 3 I 
716 3 I 3 I 3 I 3 I 
727 3 I 3 I 3 I 3 I 
777 3 I 3 I 3 I 3 I 
 
Isolate 
MTZ+DOX+CTX+FLC MTZ+DOX+FLC+CTX 
∑ FIC Activity ∑ FIC Activity 
63 4 I 4 I 
94 4 I 4 I 
95 4 I 4 I 
264 4 I 4 I 
304 4 I 4 I 
652 4 I 4 I 
696 4 I 4 I 
716 4 I 4 I 
727 4 I 4 I 
777 4 I 4 I 
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CHAPTER FIVE 
5.1 DISCUSSION 
Metronidazole resistance as well as treatment failure has been reported as early as 1962, after 
its introduction [18, 33, 54]. The nitroimidazoles metronidazole and tinidazole are the only 
antimicrobials approved by the FDA for treating trichomoniasis [55] while in South Africa 
only metronidazole is registered by the Medicine Council for this indication. It has also been 
reported that T. vaginalis infection is associated with increased risk of HIV acquisition [7, 9, 
10, 19, 20] transmission and cervical cancer [10, 28]. Therefore, there is a great need for 
alternative therapeutic agents that can be used to effectively treat trichomoniasis.     
There is no clear association between in-vitro resistance and treatment failure. Also, in-vitro 
susceptibility does not equate response to treatment. In a study by Naidoo and Sturm [52], 5 of 
6 patients infected with a metronidazole-resistant T. vaginalis responded to treatment with 
eradication of the organism while 4 of 28 patients whose organism was susceptible remained 
symptomatic and infected. It was postulated that response to treatment of patients with a 
resistant organism could be the result of concentrations of metronidazole in the vaginal 
secretions above the breakpoint used to interpret the susceptibility tests. Alternatively, drugs 
administered in combination with metronidazole in the syndromic management (SM) regimen 
could work synergistically. 
 In this study, we investigated the latter hypothesis by testing the effect of antibiotics used in 
syndromic management of VDS in South Africa in combination on T. vaginalis isolates. These 
are metronidazole, doxycycline and ceftriaxone. In the new guidelines doxycycline has been 
replaced with azithromycin [16] but this drug was not included in this study. Fluconazole was 
included since this drug is often added to the SM combination.  
43 
 
The findings of this study show that ceftriaxone and fluconazole had no antitrichomonal 
activity. These findings correlate with those of Naidoo and Sturm [52]. There was no additional 
effect of ceftriaxone or fluconazole in combination with metronidazole. Doxycycline had an 
effect against T. vaginalis even though the effect was seen at higher concentrations that are 
considered resistant for bacterial isolates.   
Using the Upcroft and Upcroft breakpoints [10], Naidoo and Sturm found 57% of 160 isolates 
susceptible, 32% intermediate and 11% resistant to metronidazole  [52]. The ten isolates used 
for our synergy test project were stored susceptible isolates that were part of a study done in 
2015 by Mtshali et al. [56]. This included 94 isolates and, using the same breakpoints, the 
results were with 55 % susceptible, 27 % intermediate and 12 % resistant, similar to those of 
Naidoo and Sturm, 10 years earlier.   
Reports on the association between in-vitro susceptibility test results and response to treatment 
are conflicting. Naidoo and Sturm [52] and Schwebke and Barrientes [57] found that there was 
no correlation between in vitro resistance and treatment outcome. In the study by Naidoo and 
Sturm, out of six patients that were infected with resistant isolates, only one patient had 
treatment failure. The other five patients responded to treatment [52]. Lossick et al. reported 
that in vitro metronidazole susceptibility values provide a relative estimate of the antibiotic-
dosage required for treatment and the level of clinical resistance [58].  In their study, 87% 
(n=53) of patients infected with clinically resistant T. vaginalis were cured with doses of 
metronidazole as high 3g of metronidazole per day for approximately 13 days. They also found 
that aerobic Minimal Lethal Concentrations (MLCs) were best suitable or accurate in 
estimating in vivo resistance of T. vaginalis isolates compared to anaerobic MLCs [58]. 
However, it is difficult to test T. vaginalis under aerobic conditions. In this study, we attempted 
incubating T. vaginalis aerobically in a 37oC; 5% CO2 incubator. There was no trichomonal 
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growth after 48 and 72 hours of incubation. The findings of a study conducted by Muller et al. 
also demonstrate that clinical resistance does not correlate with in vitro susceptibility [59].  
Doxycycline is a broad-spectrum antimicrobial that is derived from tetracycline. It has been 
shown to have anti-protozoal activity and it is used in malaria prophylaxis since 1994 [60]. In 
this study, doxycycline had some antitrichomonal activity with MICs of 64 and 128 µg/mL. In 
a study conducted by Naidoo and Sturm [52], 33% of isolates tested had an MIC of ≤ 8 µg/mL. 
The concentration of 8 µg/ml has been shown to be achievable in plasma or serum with a dose 
of 500mg, orally [52].  A study by Mahdi et al. showed that doxycycline has no antitrichomonal 
activity in vivo. In this study, only three patients were treated with 200mg of doxycycline. 
Interestingly, they found that the tetracycline derivative, oxytetracycline was effective against 
T. vaginalis in vitro [61].  The effect of this antimicrobial needs to be further investigated with 
a larger sample size.  
Antibiotic combination therapy is getting more attention with the increase in infections that are 
caused by multi-drug resistant organisms. Therefore, there is a greater need for development 
of a standardised and simple protocol for testing antibiotic combinations to different organisms 
[49]. The checkerboard assay is the commonly used technique for assessing synergism of 
antimicrobials. This technique has not been previously used for assessing the effect 
combination therapy on T. vaginalis. The major disadvantage of this techniques is that it is 
labour intensive [50]. The E-test method has also been used to assess synergism of 
antimicrobials. This method has been reported to be less time consuming [51] and it can be 
performed routinely in laboratories [51, 62]. However, this method cannot be used for T. 
vaginalis because it is performed on solid agar.    
In this study, we designed the checkerboard assay using the method described by Orhan [51]. 
This method results in each well containing two antimicrobials with different concentrations. 
In a recent study by El-Azizi, they describe a method for testing synergism that they report as 
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simple and rapid for testing double and triple antimicrobial combinations [49]. Briefly, they 
used one 96-well plate to test susceptibility to each antimicrobial alone and in combination of 
two and three antimicrobials. After adding 50µl of growth medium to each well, they added 
50µl of antimicrobials at 4x the highest concentration (alone, double and triple combination). 
These were then serially diluted and then 50µl of the inoculum was added. However, this 
technique does not result in a checkerboard and few concentration combinations may be tested.  
Researchers use different FIC Index values to interpret synergism, antagonism and / or 
indifference. Orhan describes synergism as an antibiotic combination with an FIC index of 0.5, 
indifference when the FIC index is 0.5-2, and antagonism when the FIC index is ≥2 [51]. El-
Azizi; Mackay et al. and White et al. defined synergism as combination with an FIC index of 
0.5 or less, indifference when the FIC index is greater than 0.5 but less than 4, and antagonism 
when the FIC index is greater than 4 [49, 50, 62]. In this study, we used the latter interpretation.  
The results obtained in this study suggest that all the combinations of two antimicrobials tested 
had an indifferent effect on the T. vaginalis isolates. However, with metronidazole and 
doxycycline combination there was a decrease in the MICs of both antibiotics in combination 
for some isolates. For metronidazole, there was a decrease in MICs of all isolates. Five isolates 
had MICs that were one dilution below the MIC obtained with metronidazole alone and five 
had MICs of ≤ 0.0625µg/mL in combination with doxycycline. Although based on the FIC 
index the effect of this combination is indifferent, this might suggest that these two antibiotics 
have some synergistic effect. This needs to be further investigated with a larger sample size. 
All other combinations (three and four antimicrobials) also had an indifferent effect on T. 
vaginalis. Azithromycin has also been shown to have some inhibitory effect on T. vaginalis 
[52]. Possible synergistic effect with this drug and metronidazole needs to be investigated.  
Since there are limited treatment options for trichomoniasis, it is essential that other 
antimicrobial combinations are investigated.  
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Several antimicrobials have been shown to have antitrichomonal activity. These include other 
5-nitroimidazoles (tinidazole, ornidazole) [17], furazolidone [4, 17, 54, 63], anisomycin, and 
mebendazole [63]. These antimicrobials may be useful alternatives for treating T. vaginalis 
infections resistant to metronidazole and for patients with allergic reactions to metronidazole. 
These may further be investigated for combination therapy with metronidazole.  
The limitation in this study was that out of the 94 T. vaginalis isolates that were available in 
the Medical Microbiology laboratory, only few isolates could be revived. We were planning to 
use five isolates that are resistant and five susceptible isolates as previously tested in the 
department. However, this could not be achieved since most of the isolates could not be 
revived. The other limitation was that since the checkerboard assay is labour extensive, only a 
few isolates could be tested. In this study, we aimed to perform the experiments aerobically 
and anaerobically. However, this was not achievable since the revived T. vaginalis isolates did 
not grow aerobically, even after incubation in permeable plastic bags.  We used bacterial 
controls in this study to confirm that all calculations and dilutions were accurate. For the other 
antimicrobials, bacterial controls were used because Trichomonas vaginalis strains with known 
MIC values were not available.  
 
5.2 CONCLUSION  
Our findings indicate that the combinations of antimicrobials used in syndromic management 
of the Vaginal Discharge Syndrome have an indifferent effect on T. vaginalis isolates. The 
decrease in MICs of metronidazole and doxycycline in their combination suggests that these 
two antimicrobials have some degree of synergism although it was interpreted as indifferent 
by the FIC Indices. Therefore, it is essential to further investigate this combination with a larger 
sample size. Given that treatment choices are limited for trichomoniasis, more combination 
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studies of metronidazole and the other antimicrobials that have been shown to have 
antitrichomonal effect need to be conducted.  
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APPENDICES 
 
APPENDIX A  
 
Diamond’s TYM Medium preparation (1 Litre) 
20g BBL™ trypticase peptone 
10g Yeast extract  
5g Maltose  
1g L-cysteine hydrochloride  
0.2g L-ascorbic acid   
0.5g Agar  
900ml Distilled water  
All the powder components were dissolved in 900ml distilled water and adjusted to a pH of 
6.0. The medium was then autoclaved at 121oC for 15 minutes and cooled to 50oC in the water 
bath. 100ml of heat inactivated horse serum was then added. The medium was then aliquoted 
into 5ml in polystyrene 15ml tubes and stored at 4oC.  
Antimicrobials were not added in the medium that was to be used for susceptibility testing. If 
contamination was observed in cultures then vancomycin (5 µg/ml), amphotericin B (5 µg/ml), 
amikacin (4 µg/ml), chloramphenicol (1 µg/ml) and ciprofloxacin (2 µg/ml) was added in the 
medium during preparation.  
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APPENDIX B 
Antimicrobial Agents 
1. Antimicrobial Agents stock preparation 
Antimicrobial stocks for media supplementation were prepared as shown in table 1. The 
powder for each antimicrobial was weighed and dissolved in the appropriate solvent. The 
stocks were then stored at -20oC. 
 
Table 1: Preparation of antimicrobials for media supplementation  
Antimicrobial Solvent Purity Stock concentration 
(µg/ml) 
Concentration in 
Diamonds medium 
(µg/ml) 
Amikacin Water 100 400 4 
Amphotericin B DMSO 80 500 5 
Ciprofloxacin Acetic acid 98 200 2 
Chloramphenicol Ethanol 98 100 1 
Vancomycin Water 100 500 5 
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APPENDIX C 
 
Table1 was used to score T. vaginalis growth after 48 and 72 hours of incubation. The MIC 
was the lowest antimicrobial concentration with a score of +1.  
Table 1: Scoring of Trichomonas vaginalis growth (Upcroft and Upcroft, 2001) 
Score Interpretation  
1+ 0-10 motile parasites; not more than 20% coverage of well surface  
 
2+ > 10 motile parasites; 20% to 50% coverage of the well surface  
 
3+ > 50 % coverage of the well surface = almost confluent growth with much 
motility  
 
4+ confluent growth with full motility  
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1. Combinations of two antimicrobials  
The yellow-shaded wells only had one antimicrobial. The bold highlighted 1+ score 
after 72 hours represent overgrowth or dead organisms due to overgrowth.  
1.1 Metronidazole and doxycycline combination.  
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1.2 Metronidazole and ceftriaxone combination 
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1.3 Metronidazole and fluconazole combination 
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1.4 Doxycycline and ceftriaxone combination 
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1.5 Doxycycline and fluconazole combination 
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1.6 Ceftriaxone and fluconazole combination 
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2. Combinations of three antimicrobials 
2.1 Metronidazole + Doxycycline + Fluconazole 
 
2.2 Metronidazole + Doxycycline + Ceftriaxone 
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2.3 Metronidazole + Ceftriaxone + Fluconazole 
 
 
 
2.4 Doxycycline + Ceftriaxone + Fluconazole 
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3. Combinations of four antimicrobials 
3.1 Metronidazole + Doxycycline + Fluconazole + Ceftriaxone  
 
 
3.2 Metronidazole + Doxycycline + Ceftriaxone + Fluconazole 
 
 
 
 
